Clinical trials: Intravenous Administration
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02772159
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Healthy Volunteer
A Study of RO6926496 in Healthy Volunteers
This is a single center, randomized, investigator/subject blind, single ascending dose, placebo-controlled, parallel study that will evaluate the safety, tolerability and pharmacokinetics of RO6926496 in healthy male…
- Trial name
- NCT02281786
- Testing
- RO6926496
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Inflammation
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
- Trial name
- NCT01570205
- Testing
- XG-102
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xigen SA
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Pneumonia
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired…
- Trial name
- NCT00431678
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Levofloxacin + Ceftriaxone
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 738 people
- Sponsor
- Bayer
Lung Cancer
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00005865
- Testing
- vinorelbine tartrate
- Where
- 50 sites in United States, Canada and 1 more
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression
The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days
- Trial name
- NCT03766867
- Testing
- Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day
- Where
- 13 sites in Bulgaria, Estonia and 1 more
- Volunteers
- 80 people
- Sponsor
- H. Lundbeck A/S
Cancer, Solid Tumors
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that…
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00937664
- Testing
- AZD7762, gemcitabine
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Brain Tumor
Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in…
- Trial name
- NCT02343991
- Testing
- Transcranial ExABlate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- InSightec
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
SMA
Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a…
- Trial name
- STRIVE-EU (NCT03461289)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Novartis Gene Therapies
Rheumatoid Arthritis
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD) relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses of ACZ885 and to evaluate the impact…
- Trial name
- NCT00505089
- Testing
- ACZ885
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Novartis
GI Adenocarcinoma
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
The purpose of this Phase 1 study is to determine if AMG 211 given as a continous intravenous (IV) infusion is safe and tolerable in adult participants that have advanced gastrointestinal adenocarcinoma.
- Trial name
- NCT02291614
- Testing
- AMG 211
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 45 people
- Sponsor
- Amgen
Pain, Post Surgical
A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain
The objectives of this study were to assess the analgesic efficacy and safety of parecoxib/valdecoxib on post-laparoscopic surgery analgesia.
- Trial name
- NCT00660855
- Testing
- parecoxib/valdecoxib
- Where
- 2 sites in Argentina
- Volunteers
- 4 people
- Sponsor
- Pfizer
Postoperative Pain, Hysterectomy
Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery
This study will be investigating the efficacy and safety administration of multiple doses of intravenous (IV) acetaminophen (IVAPAP) in the 48 hour period following Gynecologic Surgery.
- Trial name
- NCT00399568
- Testing
- IV Acetaminophen
- Where
- 27 sites in United States
- Volunteers
- 331 people
- Sponsor
- Mallinckrodt
Advanced or Metastatic Solid Tumors, Cancer
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice…
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Trial name
- SF112600106 (NCT00907205)
- Testing
- SF1126
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Semafore Pharmaceuticals
Severe Sepsis, Septic Shock
A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with…
- Trial name
- NCT01145560
- Testing
- AZD9773
- Where
- 52 sites in Australia, Belgium and 5 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension Due to Left Heart Disease
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
Researchers are looking for a better way to treat people who have pulmonary hypertension (PH) due to left heart disease. PH due to left heart disease is a condition of high blood pressure in the vessels of the lungs caused by…
- Trial name
- NCT06048120
- Testing
- BAY2701250 IV, BAY2701250 SC
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.